|
Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. |
|
|
Consulting or Advisory Role - AGENUS; Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Medison; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Shattuck Labs; Sutro Biopharma; Tesaro |
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Belgian Gynaecological Oncology Group (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Medimmune (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mundipharma Research (Inst); Novartis Farmacéutica (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; BioAscent; Clovis Oncology; Curio Science; Department of Defense; Eisai; Elevar Therapeutics; GlaxoSmithKline; Intuitive Surgical; McGivney Global Advisors; Merck; Mersana; Rubin, Paterniti, Gonzalez LLC; Tesaro; Toray Industries; Vaniam Group |
Research Funding - AstraZeneca (Inst); Celgene (Inst); Celsion (Inst); Clovis Oncology (Inst); Genentech (Inst); Immunogen (Inst); Merck (Inst); Takeda (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Eisai; Tesaro |
|
|
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Merck/Eisai |
Consulting or Advisory Role - GlaxoSmithKline; Merck |
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Esperas Pharma (Inst); Immunogen (Inst); IMV (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Tesaro/GSK (Inst) |
|
|
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Novartis |
Consulting or Advisory Role - GlaxoSmithKline |
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD Oncology |
|
|
Consulting or Advisory Role - Seagen |
Speakers' Bureau - Eisai; Tesaro/GSK |
Research Funding - Abbvie (Inst); Advaxis (Inst); Akeso Biopharma (Inst); Aravive (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Ellipses Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Merck (Inst); Merck Serono (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst) |
|
|
Travel, Accommodations, Expenses - Pfizer |
|
|
Employment - HM Hospitales; START |
|
Stock and Other Ownership Interests - Oncoart Associated; START |
Honoraria - HM Hospitales |
Consulting or Advisory Role - Adcendo; Alkermes; Amcure; Amunix; Anaveon; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Janssen-Cilag; MedSIR; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; PsiOxus Therapeutics; Roche/Genentech; Sanofi; Seagen; Servier; Syneos Health; T-Knife; TargImmune Therapeutics |
Research Funding - Achilles Therapeutics (Inst); BeiGene; START |
Other Relationship - Investigational Therapeutics in Oncological Sciences |
|
|
Honoraria - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Pfizer; Roche; Takeda |
Consulting or Advisory Role - Amgen; AstraZeneca; GenMab; GlaxoSmithKline; Immunogen; Merck Serono; Mersana; MSD Oncology; OncXerna Therapeutics; Seagen; Shattuck Labs |
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Clovis Oncology; GlaxoSmithKline; Incyte; Novartis; Odonate Therapeutics; Pfizer; Regeneron; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
|
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca/MedImmune (Inst) |
Other Relationship - AstraZeneca |
(OPTIONAL) Uncompensated Relationships - GlaxoSmithKline |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline/Tesaro; GOG partners; Roche/Genentech; Seagen; Tesaro |
Research Funding - GlaxoSmithKline/Tesaro (Inst) |